Advertisement

Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris

      Abstract

      Background: An excess of androgen is believed to contribute to development of acne in some patients. Because oral contraceptives (OCs) may reduce the active androgen level, hormonal therapy with OCs has been used successfully to treat patients with acne, although this treatment has previously not been studied in placebo-controlled trials. Objective: Our purpose was to evaluate the efficacy of a triphasic, combination OC (ORTHO TRI-CYCLEN [Ortho-McNeil Pharmaceutical, Raritan, N.J.], norgestimate/ethinyl estradiol) compared with placebo in the treatment of moderate acne vulgaris. Methods: Two hundred fifty-seven healthy female subjects, 15 to 49 years of age with moderate acne vulgaris, were enrolled in a multicenter, randomized, double-blind, placebo-controlled clinical trial. Each month for 6 months, subjects received either 3 consecutive weeks of the OC (i.e., tablets containing a fixed dose of ethinyl estradiol [0.035 mg] and increasing doses of norgestimate [0.180 mg, 0.215 mg, 0.250 mg]) followed by 7 days of inactive drug or placebo (color-matched tablets). Efficacy was assessed by facial acne lesion counts, an investigator’s global assessment, a subject’s self-assessment, and an analysis of within-cycle variation (cycle 6) in lesion counts. Results: Of the 160 subjects in whom efficacy could be evaluated, the OC group showed a statistically significantly greater improvement than the placebo group for all primary efficacy measures. The mean decrease in inflammatory lesion count from baseline to cycle 6 was 11.8 (62.0%) versus 7.6 (38.6%) ( p = 0.0001), and the mean decrease in total lesion count was 29.1 (53.1%) versus 14.1 (26.8%) ( p = 0.0001) in the OC and placebo groups, respectively. In the investigator’s global assessment, 93.7% of the active treatment group versus 65.4% of the placebo group were rated as improved at the end of the study ( p < 0.001). Six of the seven secondary efficacy measures (total comedones, open comedones, closed comedones, papules, pustules, and the subject’s self-assessment of study treatment) were also significantly more favorable in the OC group compared with the placebo group. Conclusion: An OC containing 0.035 mg of ethinyl estradiol combined with the triphasic regimen of norgestimate is a safe and effective treatment of moderate acne vulgaris in women with no known contraindication to OC therapy. (J Am Acad Dermatol 1997;37:746-54.)
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lucky AW
        Hormonal correlates of acne and hirsutism.
        Am J Med. 1995; 98: 89S-94S
        • Pochi PE
        Hormonal aspects of acne.
        J Int Postgrad Med. 1991; 4: 7-10
        • Lever L
        • Marks R
        Current views on the aetiology, pathogenesis and treatment of acne vulgaris.
        Drugs. 1990; 39: 681-692
        • Darley CR
        • Moore JW
        • Besser GM
        • et al.
        Androgen status in women with late onset or persistent acne vulgaris.
        Clin Exp Dermatol. 1984; 9: 28-35
        • Janaud A
        • Rouffy J
        • Upmalis D
        • et al.
        A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel.
        Acta Obstet Gynecol Scand Suppl. 1992; 156: 33-38
        • London RS
        • Chapdelaine A
        • Upmalis D
        • et al.
        Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
        Acta Obstet Gynecol Scand Suppl. 1992; 156: 9-14
        • Becker H
        Supportive European data on a new oral contraceptive containing norgestimate.
        Acta Obstet Gynecol Scand Suppl. 1990; 152: 33-39
        • Chapdelaine A
        • Desmarais J
        • Derman RJ
        Clinical evidence of the minimal androgenic activity of norgestimate.
        Int J Fertil. 1989; 34: 347-352
        • Philips A
        The selectivity of a new progestin.
        Acta Obstet Gynecol Scand Suppl. 1990; 152: 21-24
        • Plewig G
        • Kligman A
        Acne and rosacea.
        2nd ed. : Springer-Verlag, New York1993
        • Andolsek K
        Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent.
        Acta Obstet Gynecol Scand Suppl. 1992; 156: 22-26
        • Burkman R
        • Kafrissen M
        • Olson W
        • et al.
        Lipid and carbohydrate effects of a new triphasic oral contraceptive containing norgestimate.
        Acta Obstet Gynecol Scand Suppl. 1992; 156: 5-8
        • Redmond G
        • Olson W
        • Lippman J
        • Kafrissen M
        • Jones T
        • Jorizzo J
        Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial.
        Obstet Gynecol. 1997; 89: 615-622
        • Mango D
        • Ricci S
        • Manna P
        • et al.
        Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.
        Contraception. 1996; 53: 163-170
        • Wishart J
        An open study of triphasil and Diane 50 in the treatment of acne.
        Australas J Dermatol. 1991; 32: 51-54
        • Lemay A
        • Dewailly S
        • Grenier R
        • et al.
        Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel.
        J Clin Endocrinol Metab. 1990; 71: 8-14
        • Erkkola R
        • Hirvonen E
        • Luikku J
        • et al.
        Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms.
        Acta Obstet Gynecol Scand. 1990; 69: 61-65
        • Aydinlik S
        • Lachnit-Fixson U
        • Lehnert J
        Reduced estrogen ovulation inhibitor in acne therapy: double-blind study comparing Diane-35 to Diane.
        Fortschr Med. 1986; 104: 547-550
        • Miller JA
        • Wojnarowska FT
        • Dowd PM
        • et al.
        Anti-androgen treatment in women with acne: a controlled trial.
        Br J Dermatol. 1986; 114: 705-716
        • Carlborg L
        Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne: results of a multicenter study.
        Acta Obstet Gynecol Scand Suppl. 1986; 134: 29-32
        • Gammon WR
        • Meyer C
        • Lantis S
        Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris.
        J Am Acad Dermatol. 1986; 14: 183-186
        • Henderson TA
        • Olson WH
        • Leach AD
        A single-blind, randomized comparison of erythromycin pledgets and clindamycin lotion in the treatment of mild to moderate facial acne vulgaris.
        Adv Ther. 1995; 12: 172-177
        • Mandy SH
        • Vicik GJ
        • Thorne EG
        0.01% Tretinoin gel: a safe and effective topical treatment of inflammatory acne.
        Adv Ther. 1984; 1: 404-409
        • Shalita AR
        • Chalker DK
        • Ellis CN
        • et al.
        A multicenter, double-blind, controlled study of the combination of erythromycin/benzoyl peroxide, erythromycin alone, and benzoyl peroxide alone in the treatment of acne vulgaris.
        Cutis. 1992; 49: 1-4